Статті в журналах: "Immunologie du Cancer"

1

Gougis, P., C. Thibault, and L. Teixeira. "Immunologie et cancer." Oncologie 17, no. 9 (September 2015): 335. http://dx.doi.org/10.1007/s10269-015-2540-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Schneider, M. "Immunologie et cancer." Oncologie 17, no. 9 (September 2015): 402–4. http://dx.doi.org/10.1007/s10269-015-2551-y.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Fusilier, Zoé, and Hermine Ferran. "Allier les capacités anti-tumorales des CAR-T cells aux propriétés des exosomes : une approche innovante pour combattre le cancer." médecine/sciences 36, no. 6-7 (June 2020): 655–58. http://dx.doi.org/10.1051/medsci/2020116.

Повний текст джерела

Анотація:

Dans le cadre de leur module d’analyse scientifique, des étudiants de la promotion 2019-2020 des Master 2 « Immunologie Translationnelle et Biothérapies » (ITB) et « Immunologie Intégrative et Systémique » (I2S) (Mention Biologie Moléculaire et Cellulaire, Parcours Immunologie, Sorbonne Université) se sont penchés sur la littérature et ont pris la plume pour partager avec les lecteurs de m/s quelques-uns des faits marquants de l’actualité en immunologie. On y découvre ainsi les nouvelles avancées dans l’optimisation des immunothérapies à base de CAR T (thérapie cellulaire), mais également les résultats de travaux portant sur le rôle du stress ou du métabolisme sur les réponses immunitaires, et enfin des données très intéressantes sur l’impact du microbiote sur l’homéostasie du système immunitaire et la réponse aux vaccins. Plusieurs articles soulignent ainsi l’importance de la communication entre le système immunitaire et d’autres grandes fonctions physiologiques de l’organisme, en particulier le système hormonal et le métabolisme, et mettent ainsi en évidence l’intérêt d’avoir une analyse intégrative des réponses immunitaires.

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Calmels, B. "Immunologie et cancer: m�canismes d?�chappement tumoraux." Oncologie 6, no. 8 (December 2004): 525–33. http://dx.doi.org/10.1007/s10269-005-0124-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Calmels, B. "Immunologie et cancer. 1re partie: r�ponse immunitaire antitumorale." ONCOLOGIE 6, no. 7 (November 2004): 467–78. http://dx.doi.org/10.1007/s10269-004-0118-4.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Braissand, Nicolas, and Isabelle Coste. "Thérapies ciblées et immunothérapies dans le mélanome." médecine/sciences 39, no. 11 (November 2023): 889–92. http://dx.doi.org/10.1051/medsci/2023126.

Повний текст джерела

Анотація:

Dans le cadre d’un partenariat avec médecine/sciences, et pour la cinquième année consécutive, des étudiants du module d’enseignement « Immunologie, virologie et cancer » du Master Cancer de Lyon présentent une analyse d’articles scientifiques récents faisant état d’observations innovantes et importantes. Ce travail a été encadré par des chercheurs confirmés du Centre de Recherche en Cancérologie de Lyon (CRCL). Le master Cancer (université Claude Bernard Lyon1- VetAgroSup) accueille chaque année 40 étudiants en M1 et environ 80 en M2. Ce master dit « d’excellence » (master international labellisé université de Lyon) assure aux étudiants de M1 une formation en cancérologie reposant sur un socle de base commun (biologie cellulaire, moléculaire, immunologie, bio-statistique, épidémiologie, recherche translationnelle, etc.). Cette formation repose sur une forte implication des chercheurs et enseignants-chercheurs du CRCL, ainsi que sur un partenariat fort avec plusieurs instituts, dont le MIT (Massachusetts Institute of Technology, Cambridge, États-Unis), l’université d’Harvard (Boston, États-Unis), l’université de Californie à San Diego (UCSD) (États-Unis), la university of City of London (UCL), le Beatson Institute de Glasgow (Royaume-Uni), les universités de Shanghai Jiao Tong (République populaire de Chine, RPC), de Tokyo et Tohoku (Japon), de Melbourne (Australie) et d’Auckland (Nouvelle-Zélande).

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Obeid, Michel. "Allergologie-immunologie: Effets secondaires des immunothérapies du cancer : du travail pour l’immunologue clinique." Revue Médicale Suisse 15, no. 632-33 (2019): 17–19. http://dx.doi.org/10.53738/revmed.2019.15.632-33.0017.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Leclair, Lucie, and Stéphane Depil. "Les lymphocytes T CD4+ jouent un rôle majeur dans la réponse immunitaire antitumorale." médecine/sciences 37, no. 6-7 (June 2021): 671–73. http://dx.doi.org/10.1051/medsci/2021075.

Повний текст джерела

Анотація:

Cette année encore, dans le cadre d’un partenariat avec médecine/sciences, les étudiants de l’unité d’enseignement « Immunologie, virologie et cancer », dirigée par le Dr Julien Marie, au sein du Master Cancer (Université Lyon 1/VetAgroSup), présentent une analyse d’articles scientifiques récents faisant état d’observations innovantes et importantes. Ce travail de M1 a été encadré par des chercheurs immunologistes et virologistes du Centre de Recherche en Cancérologie de Lyon. Le master de cancérologie de Lyon est une formation dite d’excellence, qui accueille chaque année 30 à 40 étudiants en M1 et en M2. Ce master assure aux étudiants de M1 une formation à la cancérologie reposant sur un socle de base commun. En M2, les étudiants peuvent choisir l’une des trois spécialités suivantes : « Recherche en cancérologie », « Technologie haut débit en cancérologie » ou « Innovations thérapeutiques en cancérologie ». Créé en 2013, le Master de cancérologie de Lyon repose sur une forte implication des chercheurs et enseignants-chercheurs du laboratoire d’excellence (LabEx DEV2CAN), ainsi que sur un partenariat solide avec des laboratoires académiques situés à Oxford, Bruxelles, Tokyo, Boston, New York, San Diego, etc.

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Weber, J. S. "Cancer immunology for the non-immunologist." AACR Education book 2015, no. 1 (April 16, 2015): 89–92. http://dx.doi.org/10.1158/aacr.edb-15-7955.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Andrieu, Nathan, and Nathalie Bendriss-Vermare. "Immunothérapie et thérapies ciblées, une combinaison d’avenir dans la lutte contre le cancer." médecine/sciences 34, no. 10 (October 2018): 872–75. http://dx.doi.org/10.1051/medsci/2018217.

Повний текст джерела

Анотація:

Dans le cadre d’un partenariat avec médecine/sciences, et pour la seconde année, des étudiants du module d’immunologie virologie et cancer du Master de cancérologie de Lyon présentent une analyse d’articles scientifiques récents faisant état d’observations innovantes et importantes. Ce travail a été encadré par des chercheurs confirmés du département d’immunologie, virologie et inflammation du CRCL. Le master de cancérologie de Lyon (Lyon1-VetAgroSup) accueille chaque année 30 à 40 étudiants en M1 et en M2. Ce master dit « d’excellence » assure aux étudiants de M1 une formation à la cancérologie reposant sur un socle de base commun (biologie cellulaire, moléculaire, immunologie, bio-statistique...). En M2, les étudiants peuvent choisir l’une des trois spécialités suivantes : le Master recherche « Recherche en cancérologie », le Master recherche et professionnel « Technologie haut débit en cancérologie » et enfin le Master recherche et professionnel « Innovations thérapeutiques en cancérologie ». Le Master de cancérologie de Lyon repose sur une forte implication des chercheurs et enseignants-chercheurs du laboratoire d’excellence en développement et cancérologie (LabEx DEVweCAN), ainsi que sur un partenariat solide avec plusieurs instituts dont le MIT (Massachusetts Institute of Technology, Cambridge, États-Unis), l’université d’Harvard (Boston, États-Unis), l’université Johns Hopkins (Baltimore, États-Unis), l’Imperial College of London (Royaume-Uni), les universités de Jiao Tong (République Populaire de Chine) et de Tokyo (Japon), entre autres. Pour plus d’information : http://devwecan.universite-lyon.fr/formation/

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Clément, Léa, and Barbara Testoni. "Le dysfonctionnement mitochondrial, nouvelle cible thérapeutique pour restaurer les réponses immunitaires épuisées contre le VHB." médecine/sciences 38, no. 2 (February 2022): 223–26. http://dx.doi.org/10.1051/medsci/2022011.

Повний текст джерела

Анотація:

Dans le cadre d’un partenariat avec médecine/sciences, et pour la quatrième année consécutive, des étudiants du module d’enseignement « d’immunologie virologie et cancer » du Master de cancérologie de Lyon présentent une analyse d’articles scientifiques récents faisant état d’observations innovantes et importantes. Ce travail a été encadré par des chercheurs confirmés du Centre de Recherche en Cancérologie de Lyon (CRCL). Le Master de cancérologie (université Claude Bernard Lyon1 - VetAgroSup) accueille chaque année 40 étudiants en M1 et environ 80 en M2. Ce master dit « d’excellence » (master international labellisé Université de Lyon) assure aux étudiants de M1 une formation à la cancérologie reposant sur un socle de base commun (biologie cellulaire, moléculaire, immunologie, bio-statistique, épidémiologie, recherche translationnelle, etc.). Les étudiants de M2 peuvent choisir l’un des parcours suivants : 1) Biologie du Cancer ; 2) Innovations thérapeutiques en Cancérologie ; 3) Médecine de précision en Cancérologie ; 4) Cancer Bio-engineering. Le Master de cancérologie de Lyon repose sur une forte implication des chercheurs et enseignants-chercheurs du laboratoire d'excellence en développement et cancérologie (LabEx DEVweCAN), ainsi que sur un partenariat solide avec plusieurs instituts à travers le monde dont le MIT (Massachusetts Institute of Technology, Cambridge, États-Unis), l'université d'Harvard (Boston, États-Unis), l'université de San Diego (États-Unis), University of City of London (UCL), le Beatson Institute de Glasgow (Royaume-Uni), les universités de Shanghai Jiao Tong (République populaire de Chine, RPC), de Tokyo et de Tohoku (Japon), de Melbourne (Australie) et d'Auckland (Nouvelle-Zélande).

Стилі APA, Harvard, Vancouver, ISO та ін.

12

KÖvesi, György, Katalin PÁlÓczi, Klára Ónody, and Béla Fekete. "Immunologie profile of patients suffering from herpes simplex virus (HSV) -associated oral lesions treated with natural human interferon alpha (Egiferon)." Pathology & Oncology Research 3, no. 1 (March 1997): 44–46. http://dx.doi.org/10.1007/bf02893352.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Jain, Akhil, and Sajjan Rajpurohit. "Cancer immunotherapy." International Journal of Molecular and Immuno Oncology 3, no. 2 (July 25, 2018): 45. http://dx.doi.org/10.18203/issn.2456-3994.intjmolimmunooncol20183227.

Повний текст джерела

Анотація:

<p class="s4">The era has begun where oncology meets immunology. The recent advancement in the field of molecular biology has led to the discovery of various pathways through which cancer establishes, proliferates, grows, and disseminates. These pathways provided major insight for targeting specific molecules with the targeted therapies that show predicted responses. This targeted therapy is usually referred to as immunotherapy. These immunotherapies possess and display a unique set of toxicities mainly immunologic in nature and different from chemotherapies. This article focuses on mechanisms of immune activity of the body and various therapies available to boost these mechanisms.</p>

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Estavoyer, Benjamin, and Saidi Soudja. "Le microbiote intestinal de souris, un enjeu majeur dans la reproductibilité des résultats des modèles in vivo." médecine/sciences 34, no. 6-7 (June 2018): 609–11. http://dx.doi.org/10.1051/medsci/20183406027.

Повний текст джерела

Анотація:

Dans le cadre d’un partenariat avec médecine/sciences, et pour la seconde année, des étudiants du module d’immunologie virologie et cancer du Master de cancérologie de Lyon présentent une analyse d’articles scientifiques récents faisant état d’observations innovantes et importantes. Ce travail a été encadré par des chercheurs confirmés du département d’immunologie, virologie et inflammation du CRCL. Le master de cancérologie de Lyon (Lyon1-VetAgroSup) accueille chaque année 30 à 40 étudiants en M1 et en M2. Ce master dit « d’excellence » assure aux étudiants de M1 une formation à la cancérologie reposant sur un socle de base commun (biologie cellulaire, moléculaire, immunologie, bio-statistique…) En M2, les étudiants peuvent choisir l’une des trois spécialités suivantes : le Master recherche « Recherche en cancérologie », le Master recherche et professionnel « Technologie haut débit en cancérologie » et enfin le Master recherche et professionnel « Innovations thérapeutiques en cancérologie ». Le Master de cancérologie de Lyon repose sur une forte implication des chercheurs et enseignants-chercheurs du laboratoire d’excellence en développement et cancérologie (LabEx DEVweCAN), ainsi que sur un partenariat solide avec plusieurs instituts dont le MIT (Massachusetts Institute of Technology, Cambridge, États-Unis), l’université d’Harvard (Boston, États-Unis), l’université Johns Hopkins (Baltimore, États-Unis), l’Imperial College of London (Royaume-Uni), les universités de Jiao Tong (République Populaire de Chine) et de Tokyo (Japon), entre autres. Pour plus d’information : http://devwecan.universite-lyon.fr/formation/

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Thevin, Valentin, and Saidi Soudja. "Le dialogue entre les cellules souches intestinales et les lymphocytes T CD4+ module l’homéostasie des cellules souches." médecine/sciences 36, no. 1 (January 2020): 69–72. http://dx.doi.org/10.1051/medsci/2019175.

Повний текст джерела

Анотація:

Dans le cadre d’un partenariat avec médecine/sciences, et pour la troisième année, des étudiants du module d’immunologie virologie et cancer du Master de cancérologie de Lyon présentent une analyse d’articles scientifiques récents faisant état d’observations innovantes et importantes. Ce travail a été encadré par des chercheurs confirmés du département d’immunologie, virologie et inflammation du CRCL. Le master de cancérologie de Lyon (Lyon1-VetAgroSup) accueille chaque année 30 à 40 étudiants en M1 et en M2. Ce master dit « d’excellence » assure aux étudiants de M1 une formation à la cancérologie reposant sur un socle de base commun (biologie cellulaire, moléculaire, immunologie, bio-statistique...). En M2, les étudiants peuvent choisir l’une des trois spécialités suivantes : le Master recherche « Recherche en cancérologie », le Master recherche et professionnel « Technologie haut débit en cancérologie » et enfin le Master recherche et professionnel « Innovations thérapeutiques en cancérologie ». Le Master de cancérologie de Lyon repose sur une forte implication des chercheurs et enseignants-chercheurs du laboratoire d’excellence en développement et cancérologie (LabEx DEVweCAN), ainsi que sur un partenariat solide avec plusieurs instituts dont le MIT (Massachusetts Institute of Technology, Cambridge, États-Unis), l’université d’Harvard (Boston, États-Unis), l’université Johns Hopkins (Baltimore, États-Unis), l’Imperial College of London (Royaume-Uni), les universités de Jiao Tong (République Populaire de Chine) et de Tokyo (Japon), entre autres. Pour plus d’information : http://devwecan.universite-lyon.fr/formation/

Стилі APA, Harvard, Vancouver, ISO та ін.

16

de León, Joel, and Arturo Pareja. "Inmunología del cáncer II: bases moleculares y celulares de la carcinogénesis." Horizonte Médico (Lima) 19, no. 2 (June 8, 2019): 84–92. http://dx.doi.org/10.24265/horizmed.2019.v19n2.11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Duffy, A. G., and T. F. Greten. "Treating Hepatobiliary Cancer: The Immunologic Approach." Digestive Diseases 35, no. 4 (2017): 390–96. http://dx.doi.org/10.1159/000456593.

Повний текст джерела

Анотація:

Hepatobiliary cancer comprises a heterogeneous group of malignancies in which the standard treatments for advanced disease are minimally effective and evolve slowly over time. Like the majority of gastrointestinal cancers, with some notable exceptions, the impact of immune-based approaches is yet to be experienced. Notwithstanding this, the etiological background of hepatobiliary cancer - overlapping in almost every known causative or associated factor with inflammation - provides a strong clue that these approaches may have an impact on this group of diseases. This review seeks to put the management of hepatobiliary cancers in the context of its inflammation-based etiology, with the aim of pointing to the therapeutic opportunities in immune-based approaches currently entering the clinic or those that are about to do so.

Стилі APA, Harvard, Vancouver, ISO та ін.

18

López Alfonso, Juan Carlos, Jan Poleszczuk, Rachel Walker, Sungjune Kim, Shari Pilon-Thomas, Jose J. Conejo-Garcia, Hatem Soliman, Brian Czerniecki, Louis B. Harrison, and Heiko Enderling. "Immunologic Consequences of Sequencing Cancer Radiotherapy and Surgery." JCO Clinical Cancer Informatics, no. 3 (December 2019): 1–16. http://dx.doi.org/10.1200/cci.18.00075.

Повний текст джерела

Анотація:

PURPOSE Early-stage cancers are routinely treated with surgery followed by radiotherapy (SR). Radiotherapy before surgery (RS) has been widely ignored for some cancers. We evaluate overall survival (OS) and disease-free survival (DFS) with SR and RS for different cancer types and simulate the plausibility of RS- and SR-induced antitumor immunity contributing to outcomes. MATERIALS AND METHODS We analyzed a SEER data set of early-stage cancers treated with SR or RS. OS and DFS were calculated for cancers with sufficient numbers for statistical power (cancers of lung and bronchus, esophagus, rectum, cervix uteri, corpus uteri, and breast). We simulated the immunologic consequences of SR, RS, and radiotherapy alone in a mathematical model of tumor-immune interactions. RESULTS RS improved OS for cancers with low 20-year survival rates (lung: hazard ratio [HR], 0.88; P = .046) and improved DFS for cancers with higher survival (breast: HR = 0.64; P < .001). For rectal cancer, with intermediate 20-year survival, RS improved both OS (HR = 0.89; P = .006) and DFS (HR = 0.86; P = .04). Model simulations suggested that RS could increase OS by eliminating cancer for a broader range of model parameters and radiotherapy-induced antitumor immunity compared with SR for selected parameter combinations. This could create an immune memory that may explain increased DFS after RS for certain cancers. CONCLUSION Study results suggest plausibility that radiation to the bulk of the tumor could induce a more robust immune response and better harness the synergy of radiotherapy and antitumor immunity than postsurgical radiation to the tumor bed. This exploratory study provides motivation for prospective evaluation of immune activation of RS versus SR in controlled clinical studies.

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Ji, Haizhou, Mi Ren, Tongyu Liu, and Yang Sun. "Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment." Disease Markers 2021 (November 19, 2021): 1–21. http://dx.doi.org/10.1155/2021/5350232.

Повний текст джерела

Анотація:

Objective. Uncovering genetic and immunologic tumor features is critical to gain insights into the mechanisms of immunotherapeutic response. Herein, this study observed the functions of CXCR2 in prognosis and immunology of ovarian cancer. Methods. Expression, prognostic significance, and genetic mutations of CXCR2 were analyzed in diverse cancer types based on TCGA and GTEx datasets. Associations of CXCR2 expression with immune checkpoints, neoantigens, tumor mutational burden (TMB), and microsatellite instability (MSI) were evaluated across pancancer. CXCR2-relevant genes were identified, and their biological functions were investigated in ovarian cancer. Through three algorithms (TIMER, quanTIseq, and xCell), we assessed the relationships of CXCR2 with immune cell infiltration in ovarian cancer. GSEA was adopted for inferring KEGG and hallmark pathways involved in CXCR2. Results. CXCR2 presented abnormal expression in tumors than paired normal tissues across pancancer. Higher expression of CXCR2 was found in ovarian cancer. Moreover, its expression was in relation to overall survival and progression including ovarian cancer. Prominent associations of CXCR2 with immune checkpoints, neoantigens, TMB, and MSI were observed in human cancers. Somatic mutations of CXCR2 frequently occurred across pancancer. Amplification was the main mutational type of CXCR2 in ovarian cancer. CXCR2-relevant genes were markedly enriched in immunity activation and carcinogenic pathways in ovarian cancer. Moreover, it participated in modulating immune cell infiltration in the tumor microenvironment of ovarian cancer such as macrophage and immune response was prominently modulated by CXCR2. Conclusion. Collectively, CXCR2 acts as a promising prognostic and immunological biomarker as well as a novel immunotherapeutic target of ovarian cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Miller, Andrew H., Sonia Ancoli-Israel, Julienne E. Bower, Lucile Capuron, and Michael R. Irwin. "Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer." Journal of Clinical Oncology 26, no. 6 (February 20, 2008): 971–82. http://dx.doi.org/10.1200/jco.2007.10.7805.

Повний текст джерела

Анотація:

Patients with cancer experience a host of behavioral alterations that include depression, fatigue, sleep disturbances, and cognitive dysfunction. These behavioral comorbidities are apparent throughout the process of diagnosis and treatment for cancer and can persist well into the survivorship period. There is a rich literature describing potential consequences of behavioral comorbidities in patients with cancer including impaired quality of life, reduced treatment adherence, and increased disease-related morbidity and mortality. Medical complications of cancer and its treatment such as anemia, thyroid dysfunction, and the neurotoxicity of cancer chemotherapeutic agents account in part for these behavioral changes. Nevertheless, recent advances in the neurosciences and immunology/oncology have revealed novel insights into additional pathophysiologic mechanisms that may significantly contribute to the development of cancer-related behavioral changes. Special attention has been focused on immunologic processes, specifically activation of innate immune inflammatory responses and their regulation by neuroendocrine pathways, which, in turn, influence CNS functions including neurotransmitter metabolism, neuropeptide function, sleep-wake cycles, regional brain activity, and, ultimately, behavior. Further understanding of these immunologic influences on the brain provides a novel conceptual framework for integrating the wide spectrum of behavioral alterations that occur in cancer patients and may reveal a more focused array of translational targets for therapeutic interventions and future research. Such developments warrant complementary advances in identification of cancer patients at risk as well as those currently suffering, including an increased emphasis on the status of behavior as a “sixth vital sign” to be assessed in all cancer patients throughout their disease encounter.

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Garrepalli, Saritha. "Potentiation of Natural Killer Cells in Cancer Immunology and Reproductive Medicine." Cancer Research and Cellular Therapeutics 1, no. 2 (September 4, 2017): 01–02. http://dx.doi.org/10.31579/2640-1053/008.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Zhang, Jennifer, Olivia Lanchoney, Nikhil Joshi, Nune Markosyan, and Robert Vonderheide. "Abstract A67: CD40 agonism inhibits tumor growth in murine hormone receptor positive breast cancer via CD8 T cells." Cancer Immunology Research 10, no. 12_Supplement (December 1, 2022): A67. http://dx.doi.org/10.1158/2326-6074.tumimm22-a67.

Повний текст джерела

Анотація:

Abstract Breast cancer is the second most common malignancy affecting women and accounts for 15% of cancer-related mortality globally. Over 70% of breast cancers are hormone receptor (HR) positive (estrogen receptor and/or progesterone receptor positive) and human epidermal growth factor receptor 2 negative (HER2-). HR+HER2- breast cancers are poorly responsive to chemotherapy and recurrence and mortality remain high for patients with locally advanced disease. Thus, more therapeutic strategies are needed. Dendritic cell (DC) activation is an important pathway for T cell priming and subsequent improvements in immunosurveillance. In this study, we determined the ability of DC-targeted therapy with agonistic CD40 antibody to restore anti-tumor immunologic function in a murine orthotopic HR+HER2- breast cancer model. The Brpkp110 cell line was injected orthotopically into the abdominal mammary glands of 8 to 10-week-old C57BL/6 mice. Tumor-bearing mice treated with agonistic CD40 antibody (FGK4.5, 100 ug intraperitoneal) demonstrated decreased tumor growth and increased intratumoral CD8 T cells at 2 weeks. Both intratumoral DCs and tumor-associated macrophages in mice treated with agonistic CD40 were found to upregulate PD-L1 and CD40. CD8 T cell depletion abrogated the anti-tumor effect of agonistic CD40. Our data suggest that agonistic CD40 therapy may be a viable strategy for tumor inhibition and activation of anti-tumor immunity in HR+HER2- breast cancer. Citation Format: Jennifer Zhang, Olivia Lanchoney, Nikhil Joshi, Nune Markosyan, Robert Vonderheide. CD40 agonism inhibits tumor growth in murine hormone receptor positive breast cancer via CD8 T cells [abstract]. In: Proceedings of the AACR Special Conference: Tumor Immunology and Immunotherapy; 2022 Oct 21-24; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2022;10(12 Suppl):Abstract nr A67.

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Jiang, Tiantongfei, Weiwei Zhou, Zhenghong Chang, Haozhe Zou, Jing Bai, Qisen Sun, Tao Pan, Juan Xu, Yongsheng Li, and Xia Li. "ImmReg: the regulon atlas of immune-related pathways across cancer types." Nucleic Acids Research 49, no. 21 (November 10, 2021): 12106–18. http://dx.doi.org/10.1093/nar/gkab1041.

Повний текст джерела

Анотація:

Abstract Immune system gene regulation perturbation has been found to be a major cause of the development of various types of cancer. Numbers of mechanisms contribute to gene expression regulation, thus, systematically identification of potential regulons of immune-related pathways is critical to cancer immunotherapy. Here, we comprehensively chart the landscape of transcription factors, microRNAs, RNA binding proteins and long noncoding RNAs regulation in 17 immune-related pathways across 33 cancers. The potential immunology regulons are likely to exhibit higher expressions in immune cells, show expression perturbations in cancer, and are significantly correlated with immune cell infiltrations. We also identify a panel of clinically relevant immunology regulons across cancers. Moreover, the regulon atlas of immune-related pathways helps prioritizing cancer-related genes (i.e. ETV7, miR-146a-5p, ZFP36 and HCP5). We further identified two molecular subtypes of glioma (cold and hot tumour phenotypes), which were characterized by differences in immune cell infiltrations, expression of checkpoints, and prognosis. Finally, we developed a user-friendly resource, ImmReg (http://bio-bigdata.hrbmu.edu.cn/ImmReg/), with multiple modules to visualize, browse, and download immunology regulation. Our study provides a comprehensive landscape of immunology regulons, which will shed light on future development of RNA-based cancer immunotherapies.

Стилі APA, Harvard, Vancouver, ISO та ін.

24

de León, Joel, and Arturo Pareja. "Inmunología del cáncer I: bases moleculares y celulares de la respuesta inmune antitumoral." Horizonte Médico (Lima) 18, no. 3 (December 31, 2018): 80–89. http://dx.doi.org/10.24265/horizmed.2018.v18n3.11.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Nitsche, Lindsay Joyce, Sarbajit Mukherjee, Kareena Cheruvu, Cathleen Krabak, Rohit Rachala, Kalyan Ratnakaram, Priyanka Sharma, Maddy Singh, and Sai Yendamuri. "Exploring the Impact of the Obesity Paradox on Lung Cancer and Other Malignancies." Cancers 14, no. 6 (March 11, 2022): 1440. http://dx.doi.org/10.3390/cancers14061440.

Повний текст джерела

Анотація:

There is a paradoxical relationship between obesity, as measured by BMI, and many types of cancer, including non-small-cell lung cancer. Obese non-small-cell lung cancer patients have been shown to fare better than their non-obese counterparts. To analyze the multifaceted effects of obesity on oncologic outcomes, we reviewed the literature on the obesity paradox, methods to measure adiposity, the obesity-related derangements in immunology and metabolism, and the oncologic impact of confounding variables such as gender, smoking, and concomitant medications such as statins and metformin. We analyzed how these aspects may contribute to the obesity paradox and cancer outcomes with a focus on lung cancer. We concluded that the use of BMI to measure adiposity is limited and should be replaced by a method that can differentiate abdominal obesity. We also concluded that the concomitant metabolic and immunologic derangements caused by obesity contribute to the obesity paradox. Medications, gender, and smoking are additional variables that impact oncologic outcomes, and further research needs to be performed to solidify the mechanisms.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Yeh, Elizabeth S. "Special Issue: Cancer Metastasis and Therapeutic Resistance." Biomedicines 11, no. 5 (May 3, 2023): 1347. http://dx.doi.org/10.3390/biomedicines11051347.

Повний текст джерела

Анотація:

Metastasis and resistance to cancer therapeutics are critical barriers to curing cancer. This special issue entitled “Cancer Metastasis and Therapeutic Resistance” contains nine original contributions. The articles span a variety of human cancers, including breast, lung, brain, prostate, and skin and touch upon significant areas of interest such as cancer stem cell function, cancer immunology, and glycosylation.

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Slovin, Susan F. "Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration." American Society of Clinical Oncology Educational Book, no. 35 (May 2015): e275-e283. http://dx.doi.org/10.14694/edbook_am.2015.35.e275.

Повний текст джерела

Анотація:

Despite multiple immunologic approaches with peptide, protein, and DNA vaccines, no single therapy has induced complete remission or maintained durability of response in patients with castration-resistant prostate cancer (CRPC). Historically, immunotherapy has had limited effect on solid tumors with the exception of melanoma and renal cell carcinomas, which have been deemed as immunologic cancers given their potential for remissions either spontaneously or after removal of the primary lesion. There is considerable excitement about using an immunotherapy in combination with biologic agents such as checkpoint inhibitors, cytokines, other vaccines, or chemotherapy. Sipuleucel-T represents one of several novel immunologic therapeutic approaches to treat prostate cancer in addition to other solid tumors. It is the first in its class of autologous cellular therapies to demonstrate safety and an overall survival benefit in patients with asymptomatic or minimally symptomatic CRPC and represents a unique treatment method that may be further enhanced with other agents. Although sipuleucel-T can be used as a foundation on which to build and enhance future immunologic clinical trials, other exciting strategies are in development that may be easily integrated into the algorithm of current care.

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Bockamp, Ernesto, Sebastian Rosigkeit, Dominik Siegl, and Detlef Schuppan. "Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology." Cells 9, no. 9 (September 15, 2020): 2102. http://dx.doi.org/10.3390/cells9092102.

Повний текст джерела

Анотація:

Cancer immunotherapy utilizes the immune system to fight cancer and has already moved from the laboratory to clinical application. However, and despite excellent therapeutic outcomes in some hematological and solid cancers, the regular clinical use of cancer immunotherapies reveals major limitations. These include the lack of effective immune therapy options for some cancer types, unresponsiveness to treatment by many patients, evolving therapy resistance, the inaccessible and immunosuppressive nature of the tumor microenvironment (TME), and the risk of potentially life-threatening immune toxicities. Given the potential of nanotechnology to deliver, enhance, and fine-tune cancer immunotherapeutic agents, the combination of cancer immunotherapy with nanotechnology can overcome some of these limitations. In this review, we summarize innovative reports and novel strategies that successfully combine nanotechnology and cancer immunotherapy. We also provide insight into how nanoparticular combination therapies can be used to improve therapy responsiveness, to reduce unwanted toxicity, and to overcome adverse effects of the TME.

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Addissouky, Tamer A., Ibrahim El Tantawy El Sayed, Majeed M. A. Ali, Yuliang Wang, Ayman El Baz, Ahmed A. Khalil, and Naglaa Elarabany. "Can Vaccines Stop Cancer Before It Starts? Assessing the Promise of Prophylactic Immunization Against High-Risk Preneoplastic Lesions." Journal of Cellular Immunology 5, no. 4 (November 29, 2023): 127–40. http://dx.doi.org/10.33696/immunology.5.178.

Повний текст джерела

Анотація:

Background: Cancer remains a leading cause of mortality with modest declines, highlighting the need for more efficacious prevention strategies like early immunological intervention against premalignant disease. Main body of abstract: Oncogenic viruses demonstrate prophylactic vaccines can successfully reduce malignancy by blocking precipitating infections. However, most cancers lack viral etiology, requiring novel approaches targeting sporadic precancerous states to enable early immunoprevention. Preneoplastic tissues exhibit biological changes making them appealing targets for stimulating immune surveillance before additional mutations cause unconstrained proliferation. High-risk precancers also provide sources of dysregulated self-antigens. Yet challenges exist in lesion identification, overcoming tolerance, and avoiding inflammation potentially worsening progression. Multidisciplinary insights into precancer immunology, predictive biomarkers, antigen discovery, and combinatorial vaccination strategies are illuminating rational vaccine design. Despite obstacles, prophylactic immunization against early dysplastic changes holds disruptive potential if key steps advance this approach. Elucidating preneoplasia immunobiology and progression risk modeling will be critical to guide productive immune targeting while mitigating immunotherapy hazards. Thoughtful translation could eventually shift paradigms by priming immunosurveillance against peak vulnerability lesions. Short Conclusion: Advancements in precancer vaccines may profoundly expand prevention horizons. Cautious immune targeting of premalignant states could intercept progression toward widely disseminated malignancies. This warrants methodical efforts to unravel the promise of thwarting lethal cancers before they start.

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Finn, Olivera J. "Cancer Immunology." New England Journal of Medicine 358, no. 25 (June 19, 2008): 2704–15. http://dx.doi.org/10.1056/nejmra072739.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Finn, Olivera J., and Arun Prasad. "Cancer Immunology." Apollo Medicine 5, no. 3 (September 2008): 260–61. http://dx.doi.org/10.1016/s0976-0016(11)60503-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Melief, Cornelis JM, and Olivera J. Finn. "Cancer immunology." Current Opinion in Immunology 23, no. 2 (April 2011): 234–36. http://dx.doi.org/10.1016/j.coi.2011.01.003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Kodama, Masashi, and Nobukuni Terata. "Cancer Immunology." Annals of Cancer Research and Therapy 2, no. 1 (1993): 83–86. http://dx.doi.org/10.4993/acrt1992.2.83.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Shi, Lei, Kang Li, Yizhan Guo, Anirban Banerjee, Qing Wang, Ulrike M. Lorenz, Mahmut Parlak, et al. "Modulation of NKG2D, NKp46, and Ly49C/I facilitates natural killer cell-mediated control of lung cancer." Proceedings of the National Academy of Sciences 115, no. 46 (October 31, 2018): 11808–13. http://dx.doi.org/10.1073/pnas.1804931115.

Повний текст джерела

Анотація:

Natural killer (NK) cells play a critical role in controlling malignancies. Susceptibility or resistance to lung cancer, for example, specifically depends on NK cell function. Nevertheless, intrinsic factors that control NK cell-mediated clearance of lung cancer are unknown. Here we report that NK cells exposed to exogenous major histocompatibility class I (MHCI) provide a significant immunologic barrier to the growth and progression of malignancy. Clearance of lung cancer is facilitated by up-regulation of NKG2D, NKp46, and other activating receptors upon exposure to environmental MHCI. Surface expression of the inhibitory receptor Ly49C/I, on the other hand, is down-regulated upon exposure to tumor-bearing tissue. We thus demonstrate that NK cells exhibit dynamic plasticity in surface expression of both activating and inhibitory receptors based on the environmental context. Our data suggest that altering the activation state of NK cells may contribute to immunologic control of lung and possibly other cancers.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Kavanaugh, Denise Yardley, and David P. Carbone. "IMMUNOLOGIC DYSFUNCTION IN CANCER." Hematology/Oncology Clinics of North America 10, no. 4 (August 1996): 927–52. http://dx.doi.org/10.1016/s0889-8588(05)70376-2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Kossow, Kamen W., Joseph G. Bennett, and Marc S. Hoffmann. "Antimicrobial Prophylaxis in Lymphoma by Chemotherapy Regimen." Journal of Cellular Immunology 5, no. 4 (October 17, 2023): 103–15. http://dx.doi.org/10.33696/immunology.5.175.

Повний текст джерела

Анотація:

Treatment of lymphomas involves a wide variety of chemotherapy, immunotherapy, and targeted-agents tailored to disease biology and patient characteristics. Each of these regimens carry their own risk of opportunistic infections in an immunocompromised population. In addition to the treatment associated immunosuppression, lymphoma itself is immunosuppressive. Lymphoma associated immunosuppression is secondary to increased production of abnormal lymphocytes resulting in decreased production of normally functioning lymphocytes. Additionally, lymphoma cells induce both humoral and cellular immunosuppression through effects on numerous cytokines, T-cells, myeloid-derived suppressor cells, and macrophages. Clinical trials, patient co-morbidities, and institutional preferences all play a role in determining the preferred antimicrobial prophylaxis. While there is a paucity of data on systematic reviews and guidelines for standardized chemotherapy regimens in lymphoma patients, the efficacy and recommendations for antimicrobial prophylaxis in specific chemotherapy regimens for lymphoma has not been fully reviewed. According to the National Comprehensive Cancer Network, lymphoma is generally regarded as an ‘intermediate risk’ cancer with regards to overall infection risk. This results in discordance between research data and clinical practice. This is reiterated in the SIGNIFICANT trial which reported that while guidelines previously advised against fluoroquinolone prophylaxis in lymphoma and solid cancers, a survey of 3,600 physicians revealed that 45% routinely used fluoroquinolone prophylaxis despite these recommendations. This review article analyzes numerous research studies with summarization of findings and antimicrobial prophylaxis recommendations based on specific lymphoma chemotherapy regimens. With regards to each specific chemotherapy regimen assessed, indications for antibacterial, anti-viral, anti-fungal, and Pneumocystis jiroveci pneumonia (PJP) prophylaxis were determined for each regimen. The degree of immunosuppression and the necessary prophylaxis varies across different regimens and lymphoma subgroups; and thus, an individualized approach is necessary to optimize the supportive care during lymphoma treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Teixeira, Luis, Françoise Rothé, Michail Ignatiadis, and Christos Sotiriou. "Breast Cancer Immunology." Oncology Times 38, no. 9 (May 2016): 18–19. http://dx.doi.org/10.1097/01.cot.0000483221.52404.e3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Duckett, Thomas, and Arie Belldegrun. "Immunology in cancer." Current Opinion in Oncology 4, no. 1 (February 1992): 149–55. http://dx.doi.org/10.1097/00001622-199202000-00020.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Zhang, Jianying, Suxia Han, Bin Zhang, and Yi Zhang. "Cancer Immunology and Cancer Immunodiagnosis." Journal of Immunology Research 2014 (2014): 1–2. http://dx.doi.org/10.1155/2014/725691.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Ragab, Eman M., Abeer A. Khamis, Doaa M. El Gamal, and Tarek M. Mohamed. "The Regulation Impact of Naringenin-loaded Chitosan Nanoparticles on Succinate Dehydrogenase Activity in Cancer Cells." Journal of Cellular Immunology 5, no. 3 (September 27, 2023): 57–64. http://dx.doi.org/10.33696/immunology.5.169.

Повний текст джерела

Анотація:

Oxidative phosphorylation dysregulation (OXPHOS) has been demonstrated to be essential for the development of cancer. Therefore, it may be argued that chaperone and deacetylase activities modulate OXPHOS activity. For instance, a complicated network of interactions connects a cell’s bioenergetic features and neoplastic potential through the imbalance of sirtuin 3 (SIRT3) and succinate dehydrogenase (SDH) enzymatic activity in mitochondria. The studies outlined in this review indicate that targeting SDH regulators is a promising novel therapeutic strategy for this extremely resistant disease. Additionally, a viable therapeutic strategy may involve triggering the cell death mechanism in cancer cells by blocking mitochondrial metabolism with a natural substance. A naturally occurring flavonoid called naringenin (NAR) has been extensively investigated for its pharmacological properties, which include anti-tumor actions. However, due to its low bioavailability in this situation, nanoencapsulation is designed to improve NAR anticancer efficacy. NAR can be encapsulated by chitosan nanoparticles-TPP conjugates, thereby improving NAR cellular absorption and cytotoxicity against cancer cells. Consequently, we proposed naringenin nanoparticles as a novel therapeutic target for SDH regulators in cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Lotze, M. T., and S. A. Rosenberg. "The Immunologic Treatment Of Cancer." CA: A Cancer Journal for Clinicians 38, no. 2 (March 1, 1988): 68–94. http://dx.doi.org/10.3322/canjclin.38.2.68.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Ascierto, Maria, Valeria De Giorgi, Qiuzhen Liu, Davide Bedognetti, Tara L. Spivey, Daniela Murtas, Lorenzo Uccellini, et al. "An immunologic portrait of cancer." Journal of Translational Medicine 9, no. 1 (2011): 146. http://dx.doi.org/10.1186/1479-5876-9-146.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Szentirmai, Eszter, Donna Ferguson, Kim Ely, Alice Coogan, and Vivian Weiss. "Immunologic Markers of Thyroid Cancer." Journal of the American Society of Cytopathology 7, no. 5 (September 2018): S29—S30. http://dx.doi.org/10.1016/j.jasc.2018.06.071.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Baxevanis, Constantin N., Michael Papamichail, and Sonia A. Perez. "Immunologic biomarkers in prostate cancer." Human Vaccines & Immunotherapeutics 10, no. 5 (February 19, 2014): 1244–47. http://dx.doi.org/10.4161/hv.28032.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

DI SAIA, PHILIP J. "Immunologic Aspects of Gynecologic Cancer." Obstetrical & Gynecological Survey 40, no. 3 (March 1985): 111–35. http://dx.doi.org/10.1097/00006254-198503000-00001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

D'Angelo, S. P., W. D. Tap, G. K. Schwartz, and R. D. Carvajal. "Sarcoma Immunotherapy: Past Approaches and Future Directions." Sarcoma 2014 (2014): 1–13. http://dx.doi.org/10.1155/2014/391967.

Повний текст джерела

Анотація:

Sarcomas are heterogeneous malignant tumors of mesenchymal origin characterized by more than 100 distinct subtypes. Unfortunately, 25–50% of patients treated with initial curative intent will develop metastatic disease. In the metastatic setting, chemotherapy rarely leads to complete and durable responses; therefore, there is a dire need for more effective therapies. Exploring immunotherapeutic strategies may be warranted. In the past, agents that stimulate the immune system such as interferon and interleukin-2 have been explored and there has been evidence of some clinical activity in selected patients. In addition, many cancer vaccines have been explored with suggestion of benefit in some patients. Building on the advancements made in other solid tumors as well as a better understanding of cancer immunology provides hope for the development of new and exciting therapies in the treatment of sarcoma. There remains promise with immunologic checkpoint blockade antibodies. Further, building on the success of autologous cell transfer in hematologic malignancies, designing chimeric antigen receptors that target antigens that are over-expressed in sarcoma provides a great deal of optimism. Exploring these avenues has the potential to make immunotherapy a real therapeutic option in this orphan disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Karimi, Nastaran, and Seyed Javad Moghaddam. "KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions." Cells 12, no. 5 (February 26, 2023): 749. http://dx.doi.org/10.3390/cells12050749.

Повний текст джерела

Анотація:

RAS mutations are among the most common oncogenic mutations in human cancers. Among RAS mutations, KRAS has the highest frequency and is present in almost 30% of non-small-cell lung cancer (NSCLC) patients. Lung cancer is the number one cause of mortality among cancers as a consequence of outrageous aggressiveness and late diagnosis. High mortality rates have been the reason behind numerous investigations and clinical trials to discover proper therapeutic agents targeting KRAS. These approaches include the following: direct KRAS targeting; synthetic lethality partner inhibitors; targeting of KRAS membrane association and associated metabolic rewiring; autophagy inhibitors; downstream inhibitors; and immunotherapies and other immune-modalities such as modulating inflammatory signaling transcription factors (e.g., STAT3). The majority of these have unfortunately encountered limited therapeutic outcomes due to multiple restrictive mechanisms including the presence of co-mutations. In this review we plan to summarize the past and most recent therapies under investigation, along with their therapeutic success rate and potential restrictions. This will provide useful information to improve the design of novel agents for treatment of this deadly disease.

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Vrána, David, Marcel Matzenauer, Čestmír Neoral, René Aujeský, Radek Vrba, Bohuslav Melichar, Nikol Rušarová, Marie Bartoušková, and Janusz Jankowski. "From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer." International Journal of Molecular Sciences 20, no. 1 (December 20, 2018): 13. http://dx.doi.org/10.3390/ijms20010013.

Повний текст джерела

Анотація:

Esophageal and gastric cancers represent tumors with poor prognosis. Unfortunately, radiotherapy, chemotherapy, and targeted therapy have made only limited progress in recent years in improving the generally disappointing outcome. Immunotherapy with checkpoint inhibitors is a novel treatment approach that quickly entered clinical practice in malignant melanoma and renal cell cancer, but the role in esophageal and gastric cancer is still poorly defined. The principal prognostic/predictive biomarkers for immunotherapy efficacy currently considered are PD-L1 expression along with defects in mismatch repair genes resulting in microsatellite instability (MSI-H) phenotype. The new molecular classification of gastric cancer also takes these factors into consideration. Available reports regarding PD-1, PD-L1, PD-L2 expression and MSI status in gastric and esophageal cancer are reviewed to summarize the clinical prognostic and predictive role together with potential clinical implications. The most important recently published clinical trials evaluating checkpoint inhibitor efficacy in these tumors are also summarized.

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Deycmar, Simon, Bruno Gomes, Jehad Charo, Maurizio Ceppi, and J. Mark Cline. "Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy." Journal for ImmunoTherapy of Cancer 11, no. 1 (January 2023): e005514. http://dx.doi.org/10.1136/jitc-2022-005514.

Повний текст джерела

Анотація:

The complexity of cancer immunotherapy (CIT) demands reliable preclinical models to successfully translate study findings to the clinics. Non-human primates (NHPs; here referring to rhesus and cynomolgus macaques) share broad similarities with humans including physiology, genetic homology, and importantly also immune cell populations, immune regulatory mechanisms, and protein targets for CIT. Furthermore, NHP naturally develop cancers such as colorectal and breast cancer with an incidence, pathology, and age pattern comparable to humans. Thus, these tumor-bearing monkeys (TBMs) have the potential to bridge the experimental gap between early preclinical cancer models and patients with human cancer.This review presents our current knowledge of NHP immunology, the incidence and features of naturally-occurring cancers in NHP, and recent TBM trials investigating CIT to provide a scientific rationale for this unique model for human cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Pillai, Radhakrishna, Prabha Balaram, and M. Krishnan Nair. "Role of Immune Response in the Prognosis of Carcinoma of the Uterine Cervix: Can in Vitro Analysis Provide a better Framework for more Effective Management?" Tumori Journal 78, no. 2 (April 1992): 87–93. http://dx.doi.org/10.1177/030089169207800205.

Повний текст джерела

Анотація:

Cancer of the uterine cervix is the single largest female malignancy in India and also remains a major problem facing oncologists in other parts of the world. While advances in radiation therapy and surgical techniques have made the treatment of cervical carcinoma impressive, limitations to successful management still remain. In fact, the 5-year survival rate, stage for stage, has not improved in the United States or world wide in the past 40 years. With an estimated half a million women developing this disease annually, this lack of improved survival poses an international unresolved health problem. Immune response has been shown to be a major factor involved In the course of the disease for this cancer. Immunologic monitoring was also shown to be of effective value in assessing the prognosis for cervical carcinoma. We studied the various immunologic abnormalities in cervical cancer, the effects of radiation therapy on immune function, prospects of an immunologic staging system, the relationship between human papillomavirus infection and the Immune response, and the possibility of using in vitro Immunologic assessment to provide a better framework for more effective management of cancer of the uterine cervix.

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Immunologie du Cancer"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями